At 29.6% CAGR, the Asia Pacific GMP Cell Therapy Consumables Market is projected to be worth US$ 9,093.86 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific GMP cell therapy consumables market was valued at US$ 1,918.28 million in 2022 and is expected to reach US$ 9,093.86 million by 2028, registering a CAGR of 29.6% from 2022 to 2028. Growing regulatory approvals for cell and gene therapy product and increase in strategic collaborations are the critical factors attributed to the Asia Pacific GMP cell therapy consumables market expansion.

Cell therapies are constantly evolving, improving, and providing new treatment options for various disorders, such as cancer, autoimmune disorders, and neurological disorders. Immunotherapy is a new approach for cancer treatment. Cell therapies are currently being evaluated in clinical trials for various cancer types, separately and combined with other treatments. Additionally, the cellular immunotherapy targets that are being evaluated in clinical trials, new immunotherapy approaches are also being developed constantly, which is investigated through clinical trials. Since 2017, FDA approved about six chimeric antigen receptor (CAR) T-cell therapies for the treatment of blood cancer, including lymphomas, some leukemia forms, and multiple myeloma. More than 500 CAR-T and 17 chimeric antigen receptor natural killer (CAR-NK) cell trials are currently being conducted across the world, including the four CAR-T cell products—Yescarta, Tecartus, Kymriah, and Breyanzi that are already available in the market.

Moreover, academic cell GMP facilities are important for advancing immunotherapy. Hospitals and academic research institutions are the main drivers for scientific innovation and early-stage product development. Pharmaceutical companies depend majorly on hospitals and clinics for the availability of required patients to perform clinical trials using novel products and consumables. Additionally, several academic hospitals have started building their personalized patient treatment programs across the world. For instance, Tumor Infiltrating Lymphocytes (TILs) therapy, a type of immunotherapy used in clinical trials to treat advanced-stage cancer patients, has been made accessible worldwide via academic centers.

On the contrary, stringent regulatory policies hurdles the growth of Asia Pacific GMP cell therapy consumables market.

• Based on product, the Asia Pacific GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held 53.6% share of Asia Pacific GMP cell therapy consumables market in 2022, amassing US$ 1,028.74 million. It is projected to garner US$ 4,812.80 million by 2028 to expand at 29.3% CAGR during 2022–2028.
• Based on cell therapy, the Asia Pacific GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment held 58.6% share of cell therapy consumables market in 2022, amassing US$ 1,123.35 million. It is projected to garner US$ 5,229.24 million by 2028 to expand at 29.2% CAGR during 2022–2028.
• Based on process, the Asia Pacific GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held 36.2% share of cell therapy consumables market in 2022, amassing US$ 694.11 million. It is projected to garner US$ 3,296.14 million by 2028 to expand at 29.6% CAGR during 2022–2028.
• Based on end use, the Asia Pacific GMP cell therapy consumables market is segmented into clinical, commercial, and research. The clinical segment held 73.5% share of cell therapy consumables market in 2022, amassing US$ 1,409.60 million. It is projected to garner US$ 6,794.49 million by 2028 to expand at 30.0% CAGR during 2022–2028.
• Based on country, the Asia Pacific GMP cell therapy consumables market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.3% share of cell therapy consumables market in 2022. It was assessed at US$ 561.10 million in 2022 and is likely to hit US$ 2,632.67 million by 2028, exhibiting a CAGR of 29.4% during the forecast period.

Key players dominating the Asia Pacific GMP cell therapy consumables market are Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc, among others.

• In June 2021, Sartorius, through its subgroup Sartorius Stedim Biotech acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company produces and markets cell culture components, such as growth factors, cytokines, and media in GMP quality for manufacturing cell and gene therapy products. Sartorius has acquired 51% of the company and at the beginning of 2023 and 2026, it plans to acquire the remaining shares of CellGenix.

• In June 2021, CellPoint and Lonza collaborated to rapidly develop several T-cell based therapies and utilize the Cocoon Platform for clinical point-of-care manufacturing. The goal was to provide a proof of concept for point-of-care manufacturing to reduce vein-to-vein time, decrease manufacturing costs, and minimize complex shipping logistics.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com